Registration
MAYER BROWN LLP for NOVOCURE
Firm
Client
Income
—
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
General issues pertaining to Section 301 investigations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER New | Staff Assistant/Clerk - House Ways and Means 2014; Legislative Director - Rep. Mike Bishop 2015-2018 |
| WARREN PAYNE New | U.S. Intl Comm: Trade Analyst, 2002-04; Economic Advisor, 2004-07; House Ways and Means Committee; Trade Economist, 2007-09; Sr. Economist//Trade Advisor, 2009-11; Chief Economist, 2011-13; Policy Director, 2012-15 |
Tariff (miscellaneous tariff bills) TAR
General issues pertaining to Section 301 investigations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER New | Staff Assistant/Clerk - House Ways and Means 2014; Legislative Director - Rep. Mike Bishop 2015-2018 |
| WARREN PAYNE New | U.S. Intl Comm: Trade Analyst, 2002-04; Economic Advisor, 2004-07; House Ways and Means Committee; Trade Economist, 2007-09; Sr. Economist//Trade Advisor, 2009-11; Chief Economist, 2011-13; Policy Director, 2012-15 |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| NOVOCURE | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.